CompletedPHASE2, PHASE3NCT00421694
Positive Surgical Margins Rate and EGFR Family Members Expression in Prostate Cancer Treated With Bicalutamide
Studying Familial prostate cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of L'Aquila
- Principal Investigator
- Giovanni Luca Gravina, M.D.University of L'Aquila
- Intervention
- Bicalutamide(drug)
- Enrollment
- 119 target
- Eligibility
- 18-75 years · MALE
Study locations (1)
- University of L'Aquila, L’Aquila, Abruzzo, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00421694 on ClinicalTrials.govOther trials for Familial prostate cancer
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNANCT06470685Prophylactic Prostatectomy for Prostate Cancer (PPPC)Royal Marsden NHS Foundation Trust
- RECRUITINGNCT06433349A Multi-center Investigation of Family Health.Odense University Hospital
- RECRUITINGNANCT06171139Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate CancerUniversity of California, San Francisco
- ACTIVE NOT RECRUITINGNANCT04763915Improving Care After Inherited Cancer TestingVanderbilt-Ingram Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT04090528pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate CancerUniversity of Wisconsin, Madison
- ACTIVE NOT RECRUITINGPHASE2NCT03725761Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed TherapyUniversity of Wisconsin, Madison
- RECRUITINGNCT01221168Epidemiologic and Genetic Study on Familial Prostate CancerCentre de Recherche sur les Pathologies Prostatiques